Videos

Social determinants of health inhibit optimal impact of MM treatment.

Financial, clinical, and social barriers to adult RSV vaccination are explored.

Medical experts discuss the lack of RSV treatment leading to the importance of immunization.

A panel of experts discuss the state of biosimilars today and the importance of standardizing knowledge of the field.

Specialists assess how flu vaccines enhance immunity across various age groups against influenza.

Experts analyze the process by which the Advisory Committee on Immunization Practices formulates vaccine recommendations and updates them, and the implications and effects of these decisions.

Secondary pneumococcal vaccine schedules are explored by Drs Schaffner, Bridgeman, and Madison.

Dr. Bridgeman highlights approved pneumococcal vaccines and their indications.

The updated version of the Oncology Care Model (OCM) incentivizes value-based care over volume, but some wonder if it is enough.

A panel of experts discuss RSV vaccination in adults.

Drs Bridgeman and Welch highlight cost and resource impacts in health care systems driven by RSV.

Multiple myeloma clinical pathways and factors affecting patient quality of life are explored by an expert panel.

Medical experts highlight the significant impact of pharmacists in multiple myeloma treatment pathways.

Christina M. Madison, PharmD, FCCP, AAHIVP, sat down with Lydia Bailey, PharmD, BCACP, pharmacy operations manager at St. Vincent De Paul Charitable Pharmacy

Mary Bridgeman, PharmD, BCPS, BCGP, FASCP, drives a discussion around preventative measures to limit the spread of pneumococcal infection.

William Schaffner, MD, and Christina Madison, PharmD, FCCP, AAHIVP provide an overview of the identification and differential diagnosis of pneumococcal pneumonia.

An expert panel examines the distinctions among the 3 primary recommended flu vaccines for individuals aged 65 and above, assessing their efficacy compared with standard-dose flu vaccines.

Adam C. Welch, PharmD, MBA, FAPhA, evaluates the impact of yearly flu vaccinations on curtailing the spread of influenza among communities and populations.

With approximately 2 years of additional follow-up, lenvatinib plus pembrolizumab maintained robust effectiveness for nearly every patient.

Medical experts highlight the significant impact of pharmacists in multiple myeloma treatment pathways.

Experts discuss the role of proteasome inhibitors in combination therapy in the management of relapsed indolent multiple myeloma.

Dr Madison provides insights on the importance of and strategies for raising awareness to adult RSV vaccines.

Mary Bridgeman, PharmD, BCPS, BCGP, FASCP, Adam C. Welch, PharmD, MBA, FAPhA, and Christina Madison, PharmD, FCCP, AAHIVP, discuss the testing and treatment strategies for RSV.

A panel of experts discuss those most at risk for complications from the flu, and how flu vaccines may benefit them.

High-risk patient populations for pneumococcal pneumonia are discussed by Christina Madison, PharmD, FCCP, AAHIVP.

Key opinion leaders discuss factors leading to the development of novel pneumococcal vaccines.

Experts examine the yearly modifications in the formulations of flu vaccines and explore the variations in the adverse events experienced across different types of flu vaccines.

Expert Nikhil Palekar, MD, said that although the treatment is far from a cure, it is a vital first step toward other treatments for Alzheimer Disease.

Experts navigate the impact of proteasome inhibitors and anti-CD38 antibody therapies in the relapsed refractory multiple myeloma treatment landscape.

Experts highlight the use of 3- and 4-drug regimens for managing relapsed refractory multiple myeloma.